VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Options for Iron Chelation Therapy

Insights From:Morey Blinder, MD Washington University
Published: Tuesday, Nov 24, 2015


Iron chelation therapy is very effective at putting a patient in a negative iron balance, even with continued transfusions, as long as the patient can tolerate therapy, says Morey Blinder, MD. 

Several chelating agents are available. Deferoxamine, which is given intravenously or subcutaneously, is the oldest chelating agent and deferasirox, or Exjade, or a more modern therapy. Although effective, Exjade was associated with nausea, vomiting, and diarrhea, in some patients. The latest advance is a new formulation of deferasirox, called Jadenu, which has recently become available.

The greatest concern with deferasirox, in the form of Exjade, says Blinder, is adherence to therapy. Jadenu is much better tolerated in terms of gastrointestinal toxicities, and also is much easier for the patient to take. Blinder says that he is switching his patients from Exjade to the newer formulation. The response from patients has been a positive one, which Blinder finds very gratifying.
Slider Left
Slider Right


Iron chelation therapy is very effective at putting a patient in a negative iron balance, even with continued transfusions, as long as the patient can tolerate therapy, says Morey Blinder, MD. 

Several chelating agents are available. Deferoxamine, which is given intravenously or subcutaneously, is the oldest chelating agent and deferasirox, or Exjade, or a more modern therapy. Although effective, Exjade was associated with nausea, vomiting, and diarrhea, in some patients. The latest advance is a new formulation of deferasirox, called Jadenu, which has recently become available.

The greatest concern with deferasirox, in the form of Exjade, says Blinder, is adherence to therapy. Jadenu is much better tolerated in terms of gastrointestinal toxicities, and also is much easier for the patient to take. Blinder says that he is switching his patients from Exjade to the newer formulation. The response from patients has been a positive one, which Blinder finds very gratifying.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x